- Bayer's (OTCPK:BAYRY) Q1 adjusted EBITDA jumped 16% to €3.4B ($3.8B) and topped expectations of €3.07B, helped by prescription products such as eye treatment Eylea.
- Sales +0.5% to €11.9B.
- Net income +13.3% €1.51B.
- Core EPS +13.9% to €2.37.
- Bayer still expects adjusted EBITDA to increase by a medium single-digit percentage this year,
- "All segments posted gains in their operating performance," says CEO Marijn Dekkers.
- Pharmaceuticals "benefited from the very good development of its recently launched products," Bayer says, while "Crop Science outperformed the prior-year quarter despite a weak market environment (and) Animal Health posted substantial gains."
- Shares +0.5% in Frankfurt. (PR)